- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04910685
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis
This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of elenestinib (BLU-263) + symptom directed therapy (SDT) with placebo + SDT in participants with indolent systemic mastocytosis (ISM) whose symptoms are not adequately controlled by SDT. Parts 1 and 2 will enroll participants with ISM. Participants enrolled in Part 2 will roll over onto Part 3 to receive treatment with elenestinib in an open-label fashion following completion of the earlier Part. Part K will enroll participants with ISM who have previously received an approved selective KIT inhibitor. The study also includes pharmacokinetic (PK) groups that will enroll participants with ISM.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Blueprint Medicines
- Phone Number: 617-714-6707
- Email: medinfo@blueprintmedicines.com
Study Locations
-
-
-
Buenos Aires, Argentina, 1113
- Recruiting
- CHP Centro Hematologico Pavlovsky
-
Buenos Aires, Argentina, 1426
- Recruiting
- Consultorios Medicos Dr. Doreski - Fundacion Respirar
-
-
-
-
-
Garran, Australia, ACT 2605
- Recruiting
- The Canberra Hospital
-
-
Queensland
-
Woolloongabba, Queensland, Australia
- Recruiting
- Princess Alexandra Hospital
-
-
Victoria
-
Melbourne, Victoria, Australia, 3004
- Recruiting
- The Alfred Hospital
-
-
-
-
-
Linz, Austria, 4021
- Recruiting
- Kepler Universitatsklinikum, Med Campus III. Clinic of Internal Medicine 3 - Hematology and Oncology
-
-
-
-
-
Ghent, Belgium, 9000
- Recruiting
- Universitair Ziekenhuis Gent
-
La Louvière, Belgium, 7100
- Recruiting
- CHU Tivoli
-
Leuven, Belgium, 3000
- Recruiting
- UZ Leuven
-
-
Antwerpen
-
Edegem, Antwerpen, Belgium
- Recruiting
- Unitversitair Ziekenhuis Antwerpen
-
-
-
-
-
São Paulo, Brazil, 05403-010
- Recruiting
- Hospital das Clínicas da Faculdade de Medicina da USP - HCFMUSP
-
-
-
-
-
Santiago, Chile, 1410
- Recruiting
- Clinica Alemana de Santiago
-
-
-
-
-
Cali, Colombia, 760033
- Recruiting
- Fundación Valle del Lili
-
-
-
-
-
Brno, Czechia, 625 00
- Recruiting
- Fakultní nemocnice Brno, Interní hematologická a onkologická klinika
-
Prague, Czechia, 100 34
- Recruiting
- Fakultní nemocnice Královské Vinohrady, Hematologická klinika 3. LF UK v Praze a FNKV
-
-
-
-
-
Odense, Denmark, 5000
- Recruiting
- Odense University Hospital and University of Southern Denmark
-
-
-
-
-
Amiens, France, 80000
- Recruiting
- CHU Amiens-Picardie
-
Caen, France
- Recruiting
- CHU de Caen
-
Grenoble, France, 38043
- Recruiting
- CHU Grenoble
-
Limoges, France, 87042
- Recruiting
- CHU de Limoges
-
Nantes, France, 44093
- Recruiting
- CHU de Nantes
-
Paris, France, 75015
- Recruiting
- Hôpital Necker - Départementd 'HématologieA dultes
-
Paris, France, 75013
- Recruiting
- Hôpital de la Pitié Salpétrière
-
Poitiers, France, 86000
- Recruiting
- CHU de Poitiers
-
Toulouse, France
- Recruiting
- CHU Toulouse - Hopital Larrey
-
-
-
-
-
Aachen, Germany
- Recruiting
- Universitätsklinikum RWTH Aachen Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation
-
Berlin, Germany, 12203
- Recruiting
- Charité - Universitätsmedizin Berlin Institute of Allergology
-
Erlangen, Germany, 91054
- Recruiting
- University Clinic Erlangen
-
Hamburg, Germany, 20246
- Recruiting
- University Clinic Hamburg Eppendorf
-
Lübeck, Germany, 23562
- Recruiting
- Universitatsklinikum Schleswig-Holstein, Campus Lubeck
-
Mannheim, Germany, 68167
- Recruiting
- Universitätsmedizin Mannheim III. Medizinische Klinik Universität Heidelberg Medizinische Fakultät Mannheim
-
Munich, Germany, 80377
- Recruiting
- LMU Klinikum
-
München, Germany, 81675
- Recruiting
- Klinikum rechts der Isar der Technischen Universitaet Muenchen
-
-
-
-
-
Chaïdári, Greece, 12462
- Recruiting
- University General Hospital - General Hospital of West Attica
-
Thessaloniki, Greece, 57010
- Recruiting
- General Hospital of Thessaloniki "G. Papanikolaou"
-
-
-
-
-
Cork, Ireland, T12 DC4A
- Recruiting
- Cork University Hospital
-
-
-
-
-
Bologna, Italy, 40138
- Recruiting
- Unita Operativa di Ematologia AOU Policlinico S. Orsola-Malpighi
-
Catania, Italy, 95123
- Recruiting
- AOU Policlinico G.Rodolico - San Marco
-
Milan, Italy, 20122
- Recruiting
- Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
-
Pavia, Italy, 27100
- Recruiting
- S.C. Ematologia Fondazione I.R.C.C.S. Policlinico San Matteo
-
Salerno, Italy, 84131
- Recruiting
- S.S.D. Immunologia Clinica e Allergologia Azienda Ospedaliera Universitaria San Giovanni di Dio e Ruggi d'Aragona
-
Verona, Italy, 37126
- Recruiting
- Unità Operativa di Allergologia Azienda Ospedaliera Universitaria Integrata di Verona
-
Vicenza, Italy, 36100
- Recruiting
- Azienda Unita Locale Socia Sanitaria N8 Berica
-
-
Lombardy
-
Milan, Lombardy, Italy, 20122
- Recruiting
- UOC Ematologia
-
-
Tuscany
-
Florence, Tuscany, Italy, 50134
- Recruiting
- SOD Ematologia (Ambulatori)- AOUC Azienda Ospedaliero Universitaria Careggi
-
-
-
-
-
Groningen, Netherlands, 9713 GZ
- Recruiting
- University Medical Center Groningen
-
Maastricht, Netherlands, 6229 HX
- Recruiting
- Maastricht UMC+
-
-
South Holland
-
Rotterdam, South Holland, Netherlands, 3015 GD
- Recruiting
- ErasmusMC
-
-
-
-
-
Oslo, Norway, N-0424
- Recruiting
- Oslo University Hospital
-
-
-
-
-
Gdansk, Poland, 80-214
- Recruiting
- Uniwersyteckie Centrum Kliniczne Klinika Alergologii
-
Krakow, Poland, 30-688
- Recruiting
- Samodzielny Publiczny Za kład Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie
-
-
-
-
-
Lisbon, Portugal, 1169-050
- Recruiting
- Centro Hospitalar de Lisboa Central, E.P.E. - Hospital de Santo Antonio dos Capuchos
-
Porto, Portugal, 4099-001
- Recruiting
- CHUPorto, EPE - Hospital de Santo António
-
Porto, Portugal, 4200-139
- Recruiting
- Centro Hospitalar Universitario Sao Joao, E.P.E.
-
Senhora Da Hor, Portugal, 4464-513
- Recruiting
- Unidade Local de Saude de Matosinhos, EPE - Hospital Pedro Hispanc
-
-
-
-
-
Bucharest, Romania, 020125
- Recruiting
- Spitalul Clinic Colentina Bucuresti
-
Bucharest, Romania, 050098
- Recruiting
- Spitalul Universitar De Urgenta Bucuresti
-
-
-
-
-
Barcelona, Spain
- Recruiting
- Hospital Universitario Vall d'Hebron
-
Madrid, Spain, 28034
- Recruiting
- Hospital Universitario Ramon y Cajal
-
Toledo, Spain, 45071
- Recruiting
- Hospital Virgen del Valle - Instituto de Estudios de Mastocitosis de Castilla-La Mancha
-
-
-
-
-
Stockholm, Sweden, 141 57
- Recruiting
- Karolinska Universitetssjukhuset Huddinge
-
Uppsala, Sweden, 751 85
- Recruiting
- Uppsala University Hospital
-
-
-
-
-
Basel, Switzerland, C-4031
- Recruiting
- University Hospital Basel
-
Lucerne, Switzerland, 6000
- Recruiting
- Luzerner Kantonsspital
-
-
-
-
-
Ankara, Turkey (Türkiye), 06620
- Recruiting
- Ankara Universitesi Tip Fakultesi Cebeci Hastanesi
-
Istanbul, Turkey (Türkiye), 34093
- Recruiting
- lstanbul Universitesi lstanbul Tip Fakultesi Hastanesi
-
Mersin, Turkey (Türkiye), 33200
- Recruiting
- Mersin VM Medikal Park Hastanesi
-
-
-
-
-
Birmingham, United Kingdom, B15 2GW
- Recruiting
- Queen Elizabeth Hospital, University Hospital Birmingham
-
London, United Kingdom, SE1 7EH
- Recruiting
- Guy's and St Thomas's NHS Foundation Trust
-
London, United Kingdom, NW1 2PG
- Recruiting
- University College London Hospitals (UCLH), Haematology Cancer Clinical Trials Unit
-
Oxford, United Kingdom, OX4 6LB
- Recruiting
- GenesisCare
-
Plymouth, United Kingdom, PL6 8DH
- Recruiting
- University Hospital Plymouth Trust - Derriford Hospital
-
-
Wales
-
Cardiff, Wales, United Kingdom, CF14 4XW
- Recruiting
- University Hospital of Wales
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- Recruiting
- University of Alabama at Birmingham
-
-
California
-
La Jolla, California, United States, 92037
- Recruiting
- Orso Health, Modena Allergy and Asthma Inc
-
Los Angeles, California, United States, 90095
- Recruiting
- David Geffen School of Medicine at UCLA
-
Palo Alto, California, United States, 94305
- Recruiting
- Stanford Cancer Institute
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- UCHealth Blood Disorders and Cell Therapies Center - Anschutz Medical Campus
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Winship Cancer Institute, Emory University
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Brigham and Women's Hospital
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Recruiting
- Michigan Medicine University of Michigan
-
-
Minnesota
-
Rochester, Minnesota, United States, 55902
- Recruiting
- Mayo Clinic
-
-
New York
-
Buffalo, New York, United States, 14263
- Recruiting
- Roswell Park Cancer Institute
-
New York, New York, United States, 10032
- Recruiting
- Columbia University Medical Center
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Recruiting
- Duke Asthma, Allergy and Airway Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- Recruiting
- University of Cincinnati Medical Center
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- The University of Texas, MD Anderson Cancer Center
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Recruiting
- Huntsman Cancer Institute, University of Utah
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
All Participants:
-Participant must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 2.
Part 1 and PK groups:
- Participant has confirmed diagnosis of ISM, confirmed by Central Pathology Review
- Participant must have failed to achieve adequate symptom control for 1 or more Baseline symptoms, as determined by the Investigator, with at least 2 of the following symptom-directed therapies administered: H1 blockers, H2 blockers, proton-pump inhibitors, leukotriene inhibitors, cromolyn sodium, corticosteroids, or omalizumab.
- Participants must have SDT for ISM symptom management stabilized for at least 14 days prior to starting screening procedures.
- For participants receiving corticosteroids, the dose must be ≤ 20 mg/day prednisone or equivalent, and the dose must be stable for ≥ 14 days.
Part K:
-Participant has confirmed diagnosis of ISM, confirmed by Central Pathology Review
Part S:
-Participant has confirmed diagnosis of SSM, confirmed by Central Pathology Review of BM biopsy and central review of B- and C-findings by WHO diagnostic criteria.
Part 2:
-Participant has confirmed diagnosis of ISM, confirmed by Central Pathology Review
Key Exclusion Criteria:
- Participant has been diagnosed with any of the following WHO systemic mastocytosis (SM) sub-classifications: cutaneous mastocytosis only, SM with an associated hematologic neoplasm of non-MC lineage (SM-AHN), aggressive SM, mast cell leukemia, or mast cell sarcoma.
- Participant has been diagnosed with another myeloproliferative disorder.
- Participant has organ damage attributable to SM.
- Participant has clinically significant, uncontrolled, cardiovascular disease
- Participant has a QT interval corrected using Fridericia's formula (QTcF) > > 470 milliseconds (msec) (for females) or > 450 msec (for males).
- Participant has a history of a primary malignancy that has been diagnosed or required therapy within 3 years. The following prior malignancies are not exclusionary: completely resected basal cell and squamous cell skin cancer, curatively treated localized prostate cancer, and completely resected carcinoma in situ of any site.
- Time since any cytoreductive therapy including masitinib and midostaurin should be at least 5 half-lives or 14 days (whichever is longer), and for cladribine, interferon alpha, pegylated interferon, or antibody therapy < 28 days or 5 half-lives of the drug (whichever is longer), before beginning the screening period.
- Participant has received radiotherapy or psoralen and ultraviolet A (PUVA) therapy < 14 days before beginning the screening period.
Other protocol-defined criteria apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: (Part 1) Elenestinib Dose 1 + SDT
Participants will receive SDT and elenestinib. SDT will be determined on a per participant basis. Elenestinib will be administered orally, once daily until completion of Part 1. |
Elenestinib oral tablet
Other Names:
|
|
Experimental: (Part 1) Elenestinib Dose 2 + SDT
Participants will receive SDT and elenestinib. SDT will be determined on a per participant basis. Elenestinib will be administered orally, once daily until completion of Part 1. |
Elenestinib oral tablet
Other Names:
|
|
Experimental: (Part 1) Elenestinib Dose 3 + SDT
Participants will receive SDT and elenestinib. SDT will be determined on a per participant basis. Elenestinib will be administered orally, once daily until completion of Part 1. |
Elenestinib oral tablet
Other Names:
|
|
Placebo Comparator: (Part 1) Placebo + SDT
Participants will receive SDT and matching placebo. SDT will be determined on a per participant basis. Placebo will be administered orally, once daily until completion of Part 1. |
Placebo oral tablet |
|
Experimental: (Part 2) Elenestinib Dose 1 + SDT
Participants will receive SDT and elenestinib. SDT will be determined on a per participant basis. Elenestinib will be administered orally, once daily for approximately 48 weeks. |
Elenestinib oral tablet
Other Names:
|
|
Placebo Comparator: (Part 2) Placebo + SDT
Participants will receive SDT and matching placebo. SDT will be determined on a per participant basis. Placebo will be administered orally, once daily for approximately 48 weeks. |
Placebo oral tablet |
|
Experimental: (Part 3) Elenestinib + SDT
Participants will receive SDT and elenestinib. SDT will be determined on a per participant basis. Elenestinib will be administered orally, once daily for up to approximately 5 years. |
Elenestinib oral tablet
Other Names:
|
|
Experimental: (Part S) Elenestinib Dose 1 + SDT
Participants will receive SDT and elenestinib. SDT will be determined on a per participant basis. Elenestinib will be administered orally, once daily for up to approximately 5 years. |
Elenestinib oral tablet
Other Names:
|
|
Experimental: (Part K) Elenestinib Dose 1 + SDT
Participants will receive SDT and elenestinib. SDT will be determined on a per participant basis. Elenestinib will be administered orally, once daily for up to approximately 5 years. |
Elenestinib oral tablet
Other Names:
|
|
Experimental: (PK groups) Elenestinib + SDT
Participants will receive SDT and elenestinib. SDT will be determined on a per participant basis. Elenestinib will be administered orally, once daily for up to approximately 5 years. |
Elenestinib oral tablet
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Part 1: Number of participants with Treatment-emergent Adverse Events (TEAEs)
Time Frame: Up to 12 weeks
|
Up to 12 weeks
|
|
Part 1: Mean change from baseline in ISM-Symptom in Assessment Form (ISM-SAF) Total Symptom Score (TSS)
Time Frame: Baseline, Week 13
|
Baseline, Week 13
|
|
Part 2: Mean change from baseline in ISM-SAF TSS
Time Frame: Baseline, Week 49
|
Baseline, Week 49
|
|
Part 3: Number of participants with Adverse Events (AEs)
Time Frame: Up to 5 years
|
Up to 5 years
|
|
Part 3: Change from baseline in ISM-SAF TSS
Time Frame: Baseline up to 5 years
|
Baseline up to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Part 1: Change from baseline in serum tryptase
Time Frame: Baseline, Week 13
|
Baseline, Week 13
|
|
Part 1: Change from baseline in KIT D816V allele fraction in blood
Time Frame: Baseline, Week 13
|
Baseline, Week 13
|
|
Part 1: Change from baseline in Bone Marrow (BM) mast cells
Time Frame: Baseline, Week 13
|
Baseline, Week 13
|
|
Part 1: Mean change from baseline in ISM-SAF individual symptom scores
Time Frame: Baseline, Week 13
|
Baseline, Week 13
|
|
Part 1: Time to achieve 30% reduction from baseline in ISM-SAF TSS
Time Frame: Baseline up to Week 13
|
Baseline up to Week 13
|
|
Part 1: Time to achieve 30% reduction from baseline in ISM-SAF domain scores
Time Frame: Baseline up to Week 13
|
Baseline up to Week 13
|
|
Part 2: Proportion of participants achieving normalized tryptase
Time Frame: Baseline up to Week 49
|
Baseline up to Week 49
|
|
Part 2: Proportion of participants who achieve an undetectable level or at least a 50% reduction in KIT D816V Variant Allele Frequency (VAF)
Time Frame: Baseline up to Week 49
|
Baseline up to Week 49
|
|
Part 2: Proportion of participants achieving symptom control as defined by achieving mild symptoms
Time Frame: Baseline up to Week 49
|
Baseline up to Week 49
|
|
Part 2: Mean percent change from baseline in Bone Mineral Density (BMD)
Time Frame: Baseline, Week 49
|
Baseline, Week 49
|
|
Part 2: Mean change from baseline in the annualized rate of anaphylaxis events
Time Frame: Baseline, Weeks 25 to 48
|
Baseline, Weeks 25 to 48
|
|
Part 2: Mean change from baseline in Quality of Life (QoL) scores
Time Frame: Baseline, Week 49
|
Baseline, Week 49
|
|
Part 2: Mean change from baseline in ISM-SAF domain scores
Time Frame: Baseline, Week 49
|
Baseline, Week 49
|
|
Part 2: Number of participants with AEs
Time Frame: Up to Week 49
|
Up to Week 49
|
|
Part 2: Proportion of participants with a 50% reduction in ISM-SAF TSS
Time Frame: Baseline, Weeks 24 and 48
|
Baseline, Weeks 24 and 48
|
|
Part 2: Proportion of participants with a 50% reduction in ISM-SAF domain scores
Time Frame: Baseline, Weeks 24 and 48
|
Baseline, Weeks 24 and 48
|
|
Part 2: Proportion of participants with a 30% reduction in ISM-SAF TSS
Time Frame: Baseline, Weeks 24 and 48
|
Baseline, Weeks 24 and 48
|
|
Part 2: Proportion of participants with a 30% reduction in ISM-SAF domain scores
Time Frame: Baseline, Weeks 24 and 48
|
Baseline, Weeks 24 and 48
|
|
Part 3: Proportion of participants achieving symptom control as defined by achieving mild symptoms
Time Frame: Baseline up to 5 years
|
Baseline up to 5 years
|
|
Part 3: Change from baseline in ISM-SAF domain scores
Time Frame: Baseline, up to 5 years
|
Baseline, up to 5 years
|
|
Part 3: Proportion of participants achieving a normalized tryptase
Time Frame: Baseline up to 5 years
|
Baseline up to 5 years
|
|
Part 3: Change from baseline in BMD
Time Frame: Baseline up to 5 years
|
Baseline up to 5 years
|
|
Part 3: Change from baseline in the annualized rate of anaphylaxis events
Time Frame: Baseline up to 5 years
|
Baseline up to 5 years
|
|
Parts 2 and 3: Change from baseline in serum tryptase
Time Frame: Baseline up to 5 years
|
Baseline up to 5 years
|
|
Parts 2 and 3: Change from baseline in KIT D816V allele fraction in blood
Time Frame: Baseline up to 5 years
|
Baseline up to 5 years
|
|
Parts 2 and 3: Change from baseline in Bone Marrow (BM) mast cells
Time Frame: Baseline up to 5 years
|
Baseline up to 5 years
|
|
Parts 2 and 3: Proportion of participants achieving controlled disease
Time Frame: Baseline up to 5 years
|
Baseline up to 5 years
|
|
Parts 2 and 3: Change from baseline in skin lesions as assessed by the fractional body surface area of the most affected skin area
Time Frame: Baseline up to 5 years
|
Baseline up to 5 years
|
|
Parts 2 and 3: Change from baseline in the number of concomitant medications identified as SDT
Time Frame: Baseline up to 5 years
|
Baseline up to 5 years
|
|
Parts 2 and 3: Change from baseline in ISM-SAF Individual Symptom Scores
Time Frame: Baseline up to 5 years
|
Baseline up to 5 years
|
|
Parts 2 and 3: Change from baseline in ISM-SAF Lead (most severe) Symptom Score
Time Frame: Baseline up to 5 years
|
Baseline up to 5 years
|
|
Parts 2 and 3: Change from baseline in QoL scores
Time Frame: Baseline up to 5 years
|
Baseline up to 5 years
|
|
Part S: Number of participants with AEs
Time Frame: Baseline up to 5 years
|
Baseline up to 5 years
|
|
Part S: Proportion of participants who achieve a Pure Pathologic Response (PPR)
Time Frame: Baseline up to 5 years
|
Baseline up to 5 years
|
|
Part S: Mean change from baseline in ISM-SAF
Time Frame: Baseline, Week 25
|
Baseline, Week 25
|
|
Part K: Number of participants with AEs
Time Frame: Baseline up to 5 years
|
Baseline up to 5 years
|
|
Part K: Change from baseline in serum tryptase
Time Frame: Baseline up to 5 years
|
Baseline up to 5 years
|
|
Part K: Change from baseline in KIT D816V allele fraction in blood
Time Frame: Baseline up to 5 years
|
Baseline up to 5 years
|
|
Part K: Mean change from baseline in ISM-SAF TSS
Time Frame: Baseline up to 5 years
|
Baseline up to 5 years
|
|
Part K: Change from baseline in QoL scores
Time Frame: Baseline up to 5 years
|
Baseline up to 5 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BLU-263-1201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.